Another Nrf2 activator is 4-octyl itaconate, an analogous of itaconate with immunoregulatory and antioxidative effects produced by decarboxylating cis-aconitate
Patients should be reviewed 812 weeks after commencing treatment to assess: Symptomatic improvement, particularly resolution of fatigue and neurological symptoms Haematological response (normalisation of haemoglobin and mean cell volume) Reticulocyte count typically rises within one week, indicating bone marrow response Repeat serum B12 testing is generally not useful after starting parenteral therapy, as levels remain elevated for months
Site Irritation Because DES is injected intramuscularly into the trained muscle, injection site soreness or redness can occurespecially with repeated use in the same muscle group
Food Chem 185:389397 Smith H, Doyle S, Murphy R (2023) Target directed identification of natural bioactive compounds from filamentous fungi
Consistent with these observations, UCM05 treatment significantly reduced the clinical scores of acute vaginal injuries compared to the HSV-2 infected group, as shown in Fig
.webp)
